Login to Your Account



Nastech, P&G Add Study, Amend Osteoporosis Deal

By Karen Pihl-Carey


Wednesday, December 6, 2006
Talks of an additional trial for the parathyroid hormone nasal spray (PTH1-34) to treat osteoporosis led Nastech Pharmaceutical Co. Inc. and Procter & Gamble Pharmaceuticals Inc. to amend their 10-month-old agreement - meaning Nastech will not receive $15 million in milestone payments this year as expected. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription